carmustine has been researched along with Hearing Loss in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| "451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART." | 5.12 | Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. ( Ballman, KV; Buckner, JC; Burton, GV; Cascino, TL; Jaeckle, KA; Marshall, NE; Michalak, JC; Sandler, HM; Schomberg, PJ, 2006) |
| "Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT." | 2.67 | Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Cabanillas, F; Dicke, KA; Hagemeister, F; Horwitz, LJ; Jagannath, S; Spinolo, JA; Spitzer, G; Velásquez, W, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marshall, NE | 1 |
| Ballman, KV | 1 |
| Michalak, JC | 1 |
| Schomberg, PJ | 1 |
| Burton, GV | 1 |
| Sandler, HM | 1 |
| Cascino, TL | 1 |
| Jaeckle, KA | 1 |
| Buckner, JC | 1 |
| Spinolo, JA | 1 |
| Jagannath, S | 1 |
| Velásquez, W | 1 |
| Spitzer, G | 1 |
| Cabanillas, F | 1 |
| Hagemeister, F | 1 |
| Horwitz, LJ | 1 |
| Dicke, KA | 1 |
2 trials available for carmustine and Hearing Loss
| Article | Year |
|---|---|
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |